What is scemblix?

What is Scemblix?

Scemblix is the brand name for asciminib, an oral medicine being developed for the treatment of chronic myeloid leukemia (CML). It is designed to target the BCR-ABL1 disease-driving protein in a way intended to help patients whose leukemia has not responded adequately to other therapies or who cannot tolerate them. [1]

What type of cancer does it treat?

Scemblix is aimed at CML, a blood cancer driven by the BCR-ABL1 gene abnormality. [1]

How is Scemblix taken?

Scemblix is an oral (by mouth) therapy. [1]

Who makes Scemblix?

The drug’s development is associated with Deciphera Pharmaceuticals (as reflected in available patent/drug tracking sources). [1]

How does Scemblix fit with other CML options?

CML is commonly treated with targeted therapies aimed at blocking BCR-ABL1 signaling (for example, tyrosine kinase inhibitors). Scemblix is positioned as another targeted option specifically aimed at the BCR-ABL1 pathway, including for patients who need alternatives based on prior treatment response or tolerance. [1]

Where can I read more about the drug and its patent situation?

For drug background and patent-tracking information, DrugPatentWatch.com lists Scemblix (asciminib). [1]

Sources

1. https://www.drugpatentwatch.com/p/scemblix/